LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_007294.4:c.231G>A
BRCA1
· NP_009225.1:p.(Thr77=)
· NM_007294.4
GRCh37: chr17:41256955 C>T
·
GRCh38: chr17:43104938 C>T
Gene:
BRCA1
Transcript:
NM_007294.4
Final call
Likely Benign
BP4 supporting
BP5 supporting
BP7 supporting
Variant details
Gene
BRCA1
Transcript
NM_007294.4
Protein
NP_009225.1:p.(Thr77=)
gnomAD AF
3.7181355780957195e-06 (v4.1)
ClinVar
Likely benign
OncoKB
Classification rationale
Interpretation summary
Generated evidence synthesis
1
BP4 Supporting: synonymous p.(Thr77=) in the RING domain with SpliceAI maximum delta score 0.052.
2
BP5 Supporting: multifactorial clinical-history LR 0.3544 falls within the ENIGMA benign-supporting range.
3
BP7 Supporting: silent variant in the RING domain with BP4 met, satisfying the ENIGMA BP7 rule.
Final determination:
Under ENIGMA Table 3, at least two Supporting benign criteria satisfy Likely Benign; BP4, BP5, and BP7 provide three Supporting benign criteria, while no pathogenic rule is satisfied.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: c.231G>A is synonymous (p.Thr77=), not one of the VCEP-defined null variants, and SpliceAI max delta 0.052 is below 0.2. |
cspec
pvs1_variant_assessment
spliceai
vcep_specifications_table4_v1_2_2024_11_18
|
| PS1 | N/A | Not applicable: c.231G>A is synonymous, and SpliceAI max delta 0.052 is below the VCEP's 0.1 no-splicing threshold. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| PS2 | N/A | Not applicable: the BRCA1 VCEP explicitly says PS2 should not be used because de novo cancer occurrences lack calibration. |
cspec
|
| PS3 | Not assessed | Not assessed: no exact c.231G>A functional-assay entry or pre-assigned PS3 code was found in the governing ENIGMA datasets. |
vcep_specifications_table9_v1_2_2024_11_18
vcep_supplementarytables_v1_2_2024_11_18
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
vcep_humu_40_1557_s001
|
| PS4 | Not met | Not met: no variant-specific case-control counts, odds ratio, p-value, or confidence interval establish the VCEP requirements of p≤0.05, OR≥4, and lower CI>2.0. |
cspec
vcep_specifications_v1_2_2024_11_18
PMID:23788249
|
| PM1 | N/A | Not applicable: the ENIGMA VCEP explicitly says PM1 is not used and treats this evidence within PP3/BP4 instead. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
|
| PM2 | Not met | Not met: gnomAD v2.1 non-cancer exomes contains one allele (AF 4.22504e-06), and the VCEP says a single observation is not informative. |
cspec
vcep_appendices_v1_2_2024_11_18
gnomad_v2
|
| PM3 | Not assessed | Not assessed: no documented same-gene pathogenic variant, phase, or Fanconi Anemia phenotype is available to assign PM3 points. |
cspec
|
| PM4 | N/A | Not applicable: the variant causes no protein-length change, and the VCEP explicitly marks PM4 Do not use. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| PM5 | N/A | Not applicable: c.231G>A is synonymous, while VCEP PM5 is not used for missense changes and PM5(PTC) requires a PVS1 protein-termination variant. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_specifications_table4_v1_2_2024_11_18
|
| PM6 | N/A | Not applicable: the BRCA1 VCEP explicitly says PM6 should not be used because de novo cancer occurrences lack calibration. |
cspec
|
| PP1 | Not assessed | Not assessed: no quantitative co-segregation LR, affected-family pedigree, or informative meioses are available for this variant. |
cspec
|
| PP2 | N/A | Not applicable: the VCEP explicitly says PP2 is not used because BRCA1 has a high frequency of benign missense variants. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| PP3 | Not met | Not met: SpliceAI maximum delta score 0.052 is below the VCEP PP3 threshold of 0.2 for predicted splicing in silent variants. |
cspec
vcep_specifications_v1_2_2024_11_18
spliceai
vcep_supplementarytables_v1_2_2024_11_18
vcep_specifications_table9_v1_2_2024_11_18
PMID:22505045
|
| PP4 | Not met | Not met: Li et al. report LR 0.354419980849377, and 0.354419980849377 ≥ 2.08? no, below the VCEP PP4 Supporting threshold. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_pmid_31853058_brca1_clinical_history_lr
PMID:31853058
|
| PP5 | N/A | Not applicable: the ENIGMA VCEP prohibits PP5, so no reputable-source classification can be used for this criterion. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| BA1 | Not assessed | Not assessed: the governing rule requires non-founder FAF above 0.001 and at least 20× read depth, but neither FAF nor depth is reported. |
cspec
vcep_appendices_v1_2_2024_11_18
gnomad_v2
|
| BS1 | Not assessed | Not assessed: the governing rule requires non-founder FAF above 0.00002 and at least 20× read depth, but neither FAF nor depth is reported. |
cspec
vcep_appendices_v1_2_2024_11_18
gnomad_v2
|
| BS2 | Not assessed | Not assessed: no phenotyped clinical-cohort co-occurrence or homozygote observation meeting the VCEP's Fanconi-Anemia-unaffected points table is available. |
cspec
vcep_appendices_v1_2_2024_11_18
|
| BS3 | Not assessed | Not assessed: no exact c.231G>A functional-assay entry or pre-assigned BS3 code was found in the governing ENIGMA datasets. |
vcep_specifications_table9_v1_2_2024_11_18
vcep_supplementarytables_v1_2_2024_11_18
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
vcep_humu_40_1557_s001
|
| BS4 | Not assessed | Not assessed: no quantitative non-segregation LR, affected-family pedigree, or informative meioses are available for this variant. |
cspec
|
| BP1 | Not met | Not met: SpliceAI max delta 0.052 meets the ≤0.1 condition, but residue 77 is inside the BRCA1 RING domain spanning aa 2-101. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
|
| BP2 | N/A | Not applicable: the ENIGMA specification explicitly states that BP2 is not to be used. |
cspec
|
| BP3 | N/A | Not applicable: c.231G>A is synonymous, not an in-frame indel, and the VCEP explicitly marks BP3 Do not use. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
|
| BP4 | Met | Met at Supporting: SpliceAI maximum delta score 0.052 is below the VCEP BP4 threshold of 0.1 for a silent variant inside the RING domain. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
spliceai
vcep_supplementarytables_v1_2_2024_11_18
vcep_specifications_table9_v1_2_2024_11_18
PMID:22505045
|
| BP5 | Met | Met at Supporting: Li et al. report LR 0.354419980849377, satisfying 0.354419980849377 ≤ 0.48 and >0.23 under the VCEP BP5 range. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_pmid_31853058_brca1_clinical_history_lr
PMID:31853058
|
| BP6 | Met | Not applicable: the ENIGMA VCEP prohibits BP6, so no reputable-source benign report can be used for this criterion. |
cspec
vcep_specifications_v1_2_2024_11_18
clinvar
|
| BP7 | Met | Met at Supporting: the silent p.(Thr77=) variant meets BP4 with SpliceAI maximum delta score 0.052, satisfying the VCEP BP7 condition. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
spliceai
vcep_supplementarytables_v1_2_2024_11_18
vcep_specifications_table9_v1_2_2024_11_18
PMID:22505045
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.